Vyome Completes Merger with ReShape Lifesciences, Set to Trade on Nasdaq as HIND

Vyome Therapeutics has closed its merger with ReShape Lifesciences, and the combined company will trade on Nasdaq as Vyome Holdings under the symbol "HIND" starting August 15, 2025. Vyome is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets. The merger is expected to deliver lasting value to shareholders and transform the lives of patients with immuno-inflammatory conditions.

Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, has successfully completed its merger with ReShape Lifesciences, Inc. (Nasdaq: RSLS). The combined entity, Vyome Holdings, Inc., will commence trading on Nasdaq under the symbol "HIND" on August 15, 2025 [1].

The merger, which was approved by the Nasdaq Stock Market, will see Vyome Therapeutics leverage its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. The company's focus is on developing innovative solutions in the immuno-inflammatory space, a market with a potential exceeding $100 billion [2].

In connection with the merger, ReShape Lifesciences has declared a 1-for-4 reverse stock split. This will convert four shares of issued and outstanding common stock into one share, effective upon the commencement of trading on August 15, 2025 [1]. The new CUSIP number for the company's common stock following the reverse stock split and merger will be 92943X104.

The new board of directors for Vyome Holdings, Inc., includes four MIT alums with extensive experience in board and executive management roles. The board members are aligned with shareholders and are based in the US while having deep ties to the Indian subcontinent and advanced AI technologies [2]. The board will be led by Krishna Gupta, an MIT engineering/business alum and CEO of Remus Capital, who has a strong focus on vertical AI applications in healthcare. Shiladitya Sengupta, a MIT postgrad and serial entrepreneur, will serve as the founder. Venkat Nelabhotla, an IIM Ahmedabad alum with over 30 years of experience in pharma, biotech, and CPG industries, will be the co-founder and CEO. Mohanjit Jolly, a MIT alum and partner at Iron Pillar, will act as a shareholder. John Tincoff, a Georgetown alum and partner at Remus Capital, will also be a shareholder. Stash Pomichter, an MIT engineering dropout and member of the Remus Capital team, will complete the board [2].

Vyome Therapeutics aims to leverage its unique positioning across the US-India innovation corridor to deliver lasting value to shareholders while upholding global standards of quality and safety. The company is based in Cambridge, MA, and has announced its intent to be listed on the Nasdaq exchange under the ticker ‘HIND’ pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) on August 15, 2025 [1].

References:
[1] https://www.businesswire.com/news/home/20250813072681/en/Vyome-Announces-Nasdaq-Approval-of-Merger-with-ReShape-Lifesciences-Set-to-Begin-Trading-as-HIND
[2] https://www.ainvest.com/news/vyome-therapeutics-announces-nasdaq-approval-merger-reshape-lifesciences-2508/